Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Canellos, G. P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Canellos, G. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:S91-S93, 1996
© 1996 European Society for Medical Oncology

Reviews

Current strategies for early Hodgkin's disease

G. P. Canellos

Division of Medical Oncology, Dana-Farber Cancer Institute Boston, MA, U.S.A.

Correspondence to: G. P. Canellos, M.D. Division of Medical Oncology Dana-Farber Cancer Institute 44 Binney Street Boston, MA 02115 U.S.A.

A small percentage (~< 10%) of patients present with minimal disease that is treatable with only mantle radiotherapy. The vast majority will present with apparent local disease but will have one or another poor prognostic features necessitating staging laparotomy if only mantle/para-aortic radiation therapy is the desired approach. Otherwise, more extensive radiation including splemc fields would be required or combined modality. The unanswered questions include: (1) definition of patients who require no adjunctive radiation therapy; (2) an assessment of the actual quantity of chemotherapy needed if complementary radiation therapy is to be added; and (3) determination of whether 67gallium/SPECT scan can provide a measure of the efficacy of chemotherapy. Finally, can a less toxic regimen be substituted for ABVD in the treatment of early stage disease? Many of these questions are currently under investigation.

early stages, Hodgkin's disease, prognostic factors, therapy, treatment options


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.